ERBB2 and neoplasm: When FDA approved trastuzumab and HercepTestTM, they also approved the IHC scoring criteria for the assay, which required a strong complete membrane staining in more than 10% of the tumor cells in order to be classified as HER2 IHC3+, as shown in Table 1 (17).